

# Archived Document

This archived document is no longer being reviewed through the CLSI Consensus Document Development Process. However, this document is technically valid as of September 2016. Because of its value to the laboratory community, it is being retained in CLSI's library.




March 2010

---

## C43-A2

### Gas Chromatography/Mass Spectrometry Confirmation of Drugs; Approved Guideline—Second Edition



This document provides guidance on establishing uniform practices necessary to produce quality data for quantitation and identification of a drug or drug metabolite using the gas chromatography/mass spectrometry method. Specific quality assurance criteria for maintaining and documenting optimal instrument performance are also presented.

---

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

# Clinical and Laboratory Standards Institute

*Setting the standard for quality in medical laboratory testing around the world.*

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

## **Consensus Process**

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

## **Commenting on Documents**

CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

## **Appeals Process**

When it is believed that an objection has not been adequately considered and responded to, the process for appeals, documented in the CLSI Standards Development Policies and Processes, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

## **Get Involved—Volunteer!**

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute  
950 West Valley Road, Suite 2500  
Wayne, PA 19087 USA  
P: +1.610.688.0100  
F: +1.610.688.0700  
[www.clsi.org](http://www.clsi.org)  
[standard@clsi.org](mailto:standard@clsi.org)

ISBN 1-56238-720-0  
ISSN 0273-3099

C43-A2  
Vol. 30 No. 6  
Replaces C43-A  
Vol. 22 No. 22

---

## Gas Chromatography/Mass Spectrometry Confirmation of Drugs; Approved Guideline—Second Edition

Volume 30 Number 6

Loralie J. Langman, PhD, DABCC, ABFT, Chairholder  
Larry D. Bowers, PhD, DABCC  
Jennifer A. Collins, PhD  
Catherine A. Hammett-Stabler, PhD, DABCC, FACB  
Marc A. LeBeau, PhD

### Abstract

Clinical and Laboratory Standards Institute document C43-A2—*Gas Chromatography/Mass Spectrometry Confirmation of Drugs; Approved Guideline—Second Edition* is intended to aid the laboratorian in developing appropriate procedures for the use of gas chromatography/mass spectrometry in confirmation analyses. Its primary objective is to establish uniform practices necessary for producing quality data for quantitation and identification of a drug or drug metabolite. To support the scientific basis of the uniform practices, a brief overview of the techniques is provided. Specific quality assurance criteria for maintaining and documenting optimal instrument performance are presented.

Clinical and Laboratory Standards Institute (CLSI). *Gas Chromatography/Mass Spectrometry Confirmation of Drugs; Approved Guideline—Second Edition*. CLSI document C43-A2 (ISBN 1-56238-720-0). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2010.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at [www.clsi.org](http://www.clsi.org). If your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: [customerservice@clsi.org](mailto:customerservice@clsi.org); Website: [www.clsi.org](http://www.clsi.org).



CLINICAL AND  
LABORATORY  
STANDARDS  
INSTITUTE®

Copyright ©2010 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to [permissions@clsi.org](mailto:permissions@clsi.org).

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, e-mail [permissions@clsi.org](mailto:permissions@clsi.org).

### **Suggested Citation**

CLSI. *Gas Chromatography/Mass Spectrometry Confirmation of Drugs; Approved Guideline—Second Edition*. CLSI document C43-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2010.

### **Previous Editions:**

April 2000, November 2002

### **Archived:**

September 2016

ISBN 1-56238-720-0  
ISSN 0273-3099

## Committee Membership

### Area Committee on Clinical Chemistry and Toxicology

**David A. Armbruster, PhD,  
DABCC, FACB  
Chairholder  
Abbott Diagnostics  
Abbott Park, Illinois, USA**

**David G. Grenache, PhD,  
DABCC, FACB  
Vice-Chairholder  
University of Utah, ARUP  
Laboratories  
Salt Lake City, Utah, USA**

Yung W. Chan, MT (ASCP)  
FDA Ctr. for Devices/Rad. Health  
Rockville, Maryland, USA

Steven C. Kazmierczak, PhD,  
DABCC, FACB  
Oregon Health and Science  
University  
Portland, Oregon, USA

Loralie J. Langman, PhD  
Mayo Clinic  
Rochester, Minnesota, USA

Jeffrey E. Vaks, PhD  
Roche Molecular Diagnostics  
Pleasanton, California, USA

Hubert Vesper, PhD  
Centers for Disease Control and  
Prevention  
Atlanta, Georgia, USA

Graham Henderson White, PhD  
Flinders Medical Centre  
Bedford Park, Australia

Jack Zakowski, PhD, FACB  
Beckman Coulter, Inc.  
Brea, California, USA

#### Advisors

John Rex Astles, PhD, FACB  
Centers for Disease Control and  
Prevention  
Atlanta, Georgia, USA

David M. Bunk, PhD  
National Institute of Standards and  
Technology  
Gaithersburg, Maryland, USA

Greg Cooper, CLS, MHA  
Bio-Rad Laboratories, Inc., QSD  
Division  
Plano, Texas, USA

Paul D'Orazio, PhD  
Instrumentation Laboratory  
Bedford, Massachusetts, USA

Carl C. Garber, PhD, FACB  
Quest Diagnostics, Incorporated  
Madison, New Jersey, USA

Uttam Garg, PhD, DABCC  
Children's Mercy Hospitals and  
Clinics  
Kansas City, Missouri, USA

Claude Giroud, PhD  
Bio-Rad Laboratories, Inc.  
Marnes-La-Coquette, France

Neil Greenberg, PhD  
Ortho-Clinical Diagnostics, Inc.  
Rochester, New York, USA

Christopher M. Lehman, MD  
University of Utah Health Sciences  
Center  
Salt Lake City, Utah, USA

W. Gregory Miller, PhD  
Virginia Commonwealth University  
Richmond, Virginia, USA

Gary L. Myers, PhD  
Centers for Disease Control and  
Prevention  
Atlanta, Georgia, USA

David Sacks, MD  
Brigham and Women's Hospital  
and Harvard Medical School  
Boston, Massachusetts, USA

Thomas L. Williams, MD  
Nebraska Methodist Hospital  
Omaha, Nebraska, USA

#### Staff

Clinical and Laboratory Standards  
Institute  
Wayne, Pennsylvania, USA

Lois M. Schmidt, DA  
*Vice President, Standards  
Development*

David E. Sterry, MT(ASCP)  
*Staff Liaison*

Patrice E. Polgar  
*Project Manager*

Melissa A. Lewis, ELS  
*Editorial Manager*

Carol DiBerardino, MLA, ELS  
*Assistant Editor*

### Acknowledgment

CLSI and the Area Committee on Clinical Chemistry and Toxicology gratefully acknowledge the following individuals for their help in preparing the approved-level, second edition of this guideline:

**Loralie J. Langman, PhD  
Chairholder  
Mayo Clinic  
Rochester, Minnesota, USA**

Larry D. Bowers, PhD, DABCC  
U.S. Anti-Doping Agency  
Colorado Springs, Colorado, USA

Jennifer A. Collins, PhD  
MEDTOX Laboratories, Inc  
St. Paul, Minnesota, USA

Catherine A. Hammett-Stabler,  
PhD, DABCC, FACB  
UNC-Chapel Hill  
Chapel Hill, North Carolina, USA

Marc A. LeBeau, PhD  
FBI Laboratory  
Quantico, Virginia, USA



**Contents**

Abstract.....	i
Committee Membership.....	iii
Foreword.....	vii
1 Scope.....	1
2 Introduction.....	1
3 Standard Precautions.....	2
4 Terminology.....	2
4.1 A Note on Terminology.....	2
4.2 Definitions.....	2
4.3 Abbreviations and Acronyms.....	6
5 Principles of Gas Chromatography/Mass Spectrometry.....	6
5.1 Gas Chromatography.....	7
5.2 Interface.....	7
5.3 Mass Spectrometry.....	8
5.4 Data Acquisition.....	12
6 Method Verification.....	15
6.1 Specificity.....	15
6.2 Trueness.....	16
6.3 Carryover.....	16
6.4 Precision (Repeatability and Reproducibility).....	16
6.5 Linearity.....	17
6.6 Limit of Detection.....	17
6.7 Limit of Quantitation.....	18
6.8 Robustness.....	18
6.9 Measurement Uncertainty.....	19
7 Routine Instrument and Method Performance Validation.....	19
7.1 Gas Chromatograph.....	19
7.2 Mass Spectrometer.....	20
7.3 Calibration.....	21
7.4 Quality Control/Quality Assurance.....	22
8 Identification Principles.....	23
8.1 Gas Chromatograph.....	23
8.2 Mass Spectral Identification.....	24
References.....	27
Additional References.....	29
Summary of Consensus Comments and Working Group Responses.....	30
Summary of Delegate Comments and Working Group Responses.....	36

**Contents (Continued)**

The Quality Management System Approach .....40

Related CLSI Reference Materials .....41

## Foreword

The detection of a drug in the biological fluid of an individual can have serious professional, financial, and social consequences. As a result, it is often necessary or even required that the detection of a drug using a screening procedure be confirmed using a second method based on a different analytical or physical principle possessing greater sensitivity and specificity than the initial method used for screening. The purpose of the confirmation test is to decrease the probability of false-positive results and to provide additional information and assurance about the identity of the detected compound.

Gas chromatography/mass spectrometry (GC/MS) is widely accepted in both scientific and legal arenas as one of the most powerful analytical techniques for the separation, quantitation, and identification of drug analytes, especially at low concentrations. Technological advances have allowed introduction of bench-top GC/MS instrumentation into forensic and clinical toxicology laboratories. Further advances continue to move state-of-the-art techniques such as gas- and liquid-phase chemical ionization, tandem mass spectrometry (MS/MS), high-resolution mass spectrometry, and high-performance liquid chromatography/mass spectrometry (HPLC/MS) into routine laboratory operation. Appropriate application of these analytical tools requires that the methods used are verified for the purpose and the instruments are operating correctly.

This edition of C43 was revised to clarify concepts and terminology. Some minor content additions were also made, such as MS/MS and time-of-flight (TOF) mass spectrometry.

**NOTE:** The scope of this document is the use of GC/MS in drug confirmation analyses. By definition, it is assumed that the user is attempting to confirm a screening result obtained using another testing method.

## Key Words

Athletic drug testing, clinical toxicology, drugs of abuse, forensic toxicology, gas chromatography, magnetic sector mass spectrometer, mass spectrometry, quadrupole mass spectrometer, tandem mass spectrometry



# Gas Chromatography/Mass Spectrometry Confirmation of Drugs; Approved Guideline—Second Edition

## 1 Scope

This document is intended to aid the laboratorian in developing appropriate procedures for the use of GC/MS in drug *confirmation* analyses. By definition, it is assumed that the user is attempting to confirm a result obtained using a screening method such as immunoassay. It addresses the instrumental and methodological issues in developing a chromatographic mass spectrometric method, routine performance of the analysis, and continued quality assurance.

Guidance documents exist for laboratories involved in regulatory workplace drug-testing programs and are used in laboratories certified by these programs. Additionally, each laboratory needs to consult its own country's regulatory requirements.<sup>a</sup> However, confirmatory assays are also used in settings outside federal workplace drug testing programs, eg, by laboratories engaged in clinical toxicology, other types of forensic testing, and athletic testing. The present guideline was developed to provide assistance in developing GC/MS confirmation tests that are fit for the analytical purpose in each of these areas.

The chain of custody, although an important part of any test result to be submitted to the judicial system, *is not* discussed here. Guidelines for sample collection and screening testing have been published. Refer to CLSI document C52<sup>1</sup> for recommendations on sample collection and screening testing.

## 2 Introduction

GC/MS is generally accepted as the “gold standard” for identification and quantitation of drug analytes. As such, it is frequently used to confirm presumptive positive drug screening tests performed by immunoassay, thin-layer chromatography, HPLC, or GC. The confidence in the ability of GC/MS to provide unequivocal analytical data is based on recognition of its reproducibility, repeatability, specificity, and trace detection capabilities. Although this confidence is well founded, the measurement and identification of trace levels of compounds in biological matrices such as urine, hair, blood, bile, or organ tissue present a unique problem due to the complex and variable nature of the matrices. Because GC/MS confirmation tests are applied in areas of clinical and forensic science other than workplace drug testing, it seems appropriate to establish broader criteria.

In drug analysis, GC/MS is used either to increase confidence in the identification of an unknown compound or to improve the limits of detection or quantitation through increased analytical specificity. Because of this unique combination of identification and quantitation capabilities, GC/MS methods, particularly *confirmation* methods, require a specific set of criteria for verification of methods and for performance verification in routine analysis.

Two broad uses of drug analysis are performed with GC/MS instrumentation. In the first use, the presence or absence of a drug or drug metabolite is determined using concentration thresholds. These thresholds are based on either scientific criteria or administrative needs. When the threshold concentration, threshold ratio of amounts, or other defined parameter is exceeded, the compound is deemed to be present or to be present in nonphysiological amounts. In these cases, the performance of the method and instrument at the threshold has particular importance. The best-known example of the threshold approach was the development of specific administrative threshold concentrations and criteria for identification of five

---

<sup>a</sup>In the United States, the Division of Workplace Programs, Substance Abuse and Mental Health Services Administration of the United States Department of Health and Human Services oversees the best-known drug testing program. The US National Laboratory Certification Program provides guidance for laboratories involved in federal workplace drug testing programs.